Highlights:
- The goal of the study was to look at the antibody response in Indians after two full doses of Covishield and Covaxin.
- After two doses, both Covishield and Covaxin elicited a positive immune response: Study
- The study is a preprint and hasn’t been peer-reviewed, so it shouldn’t be used to guide clinical practice.
According to a preliminary study by Coronavirus Vaccination-induced Antibody Titre (COVAT) involving healthcare workers (HCW) who got both doses of either vaccine, the Covishield vaccine produced more antibodies than the Covaxin vaccine.
After the first dosage, Covishield recipients had considerably greater anti-spike antibody seropositivity rates than Covaxin recipients, as per the study.
Because this is a preprint that hasn’t been peer-reviewed, it shouldn’t be used to guide clinical practise.
Both vaccines, Covishield and Covaxin, generated a decent response after two doses, according to the study, although Covishield had a much higher seropositivity rate and median anti-spike antibody.
Also Read: Centre Signs Deal With Biological-E For Second Made In India Covid-19 Vaccine
As per research, “The first doses of Covishield and Covaxin were given to 456 and 96 HCW (325 Male, 227 Female) respectively. After the first dose, 79.3% of the participants were seropositive. Covishield recipients had a considerably greater responder rate and median (IQR) increase in anti-spike antibody than Covaxin recipients (84.8 vs. 43.8 percent; 61.5 vs. 6 AU/ml; both p0.001). “
The study included healthcare workers who had received one of the two vaccines, Covishield or Covaxin, and are with or without past history of SARS-CoV-2 infection.
According to the study, “This ongoing, pan-India, cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) investigation is being carried out among HCW with or without a history of SARS-CoV-2 infection. Anti-spike binding antibody to SARS-CoV-2 is being evaluated quantitatively at four timepoints, ranging from 21 days after the first dosage to 6 months after the second dose.”
The study’s conclusion, however, said that both vaccines induced a good immune response.
It stated, “While both vaccinations induced an immunological response, Covishield recipients had considerably greater anti-spike antibody seropositivity rates after the first dose than Covaxin recipients. The ongoing COVAT study will shed further insight on the immune response to the second dose of two vaccines.”
The emergency use authorisation was granted by DCGI-CDSCO in January 2021 to Bharat Biotech’s Covaxin and Oxford-Astra Zeneca’s Covishield, is being made by Serum Institute of India (India).
Bharat Biotech collaborated with the Indian Council of Medical Research (ICMR) – National Institute of Virology to create Covaxin, India’s indigenous COVID-19 vaccine (NIV). The vaccine is based on platform technology obtained from Whole-Virion Inactivated Vero Cells.
The Serum Institute charges state governments Rs 300 for a Covishield dose and private institutions Rs 600.
A Covaxin dose costs Rs 400 in states and Rs 1200 in private markets, according to Bharat Biotech.
